Bio-Techne Corporation Stock

$51.54

3.02%

Nasdaq, Jul 07, 10:00 pm CET

ISIN

US09073M1045

Symbol

TECH

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P 500

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Bio-Techne Corporation Stock price

$51.54

-15.15 22.72% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-1.61 3.02%

ISIN

US09073M1045

Symbol

TECH

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P 500

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$8.3b

Enterprise Value

$8.5b

Net debt

$189.3m

Cash

$140.7m

Shares outstanding

156.8m

Valuation (TTM | estimate)

P/E

64.8 | 27.2

P/S

6.9 | 6.7

EV/Sales

7.1 | 6.9

EV/FCF

38.6

P/B

4.1

Dividends

DPS

$0.32

Yield 1Y | 5Y

0.6% | 0.4%

Growth 1Y | 5Y

0.0% | 0.0%

Payout 1Y | 3Y

30.5% | 21.5%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$1.2b | $1.2b

EBITDA

$329.1m | $431.5m

EBIT

$218.2m | $380.8m

Net Income

$131.7m | $306.2m

Free Cash Flow

$220.8m

Growth (TTM | estimate)

Revenue

-15.5% | 7.1%

EBITDA

-24.8% | 53.2%

EBIT

-33.3% | -

Net Income

-48.2% | 82.2%

Free Cash Flow

-12.1%

EPS

$0.8

FCF per Share

$1.4

Short interest

4.5%

Employees

Rev per Employee

$370.0k

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

??

23 Analysts have issued a Bio-Techne Corporation forecast:

16x Buy

70%

7x Hold

30%

More details on Analyst Estimates Including Price Targets

23 Analysts have issued a Bio-Techne Corporation forecast:

Buy

70%

Hold

30%

Analyst Estimates with Stock Price Targets

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1,209 1,209	16% 16% 100%
- Direct Costs	406 406	14% 14% 34%
Gross Profit	803 803	16% 16% 66%
- Selling and Administrative Expenses	487 487	4% 4% 40%
- Research and Development Expense	97 97	19% 19% 8%
EBITDA	329 329	25% 25% 27%
- Depreciation and Amortization	111 111	0% 0% 9%
EBIT (Operating Income) EBIT	218 218	33% 33% 18%
Net Profit	132 132	48% 48% 11%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bio-Techne Corporation Stock News

Neutral

PRNewsWire

●

14 days ago

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS , June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy deve...

Neutral

PRNewsWire

●

28 days ago

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.

Neutral

PRNewsWire

●

about one month ago

Bio-Techne to Present at Investor Conferences

MINNEAPOLIS , May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth Stock Conference June 3, 2025 2:40 PM CDT Jefferies Global Healthcare Conference June 4, 2025 3:45 PM EDT Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM EDT A live webcast of t...

More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office	United States
CEO	Kim Kelderman
Employees	3,100
Founded	1976
Website	www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now